Inhibrx Biosciences (INBX) Asset Utilization Ratio (2024 - 2026)
Inhibrx Biosciences (INBX) posted quarterly Asset Utilization Ratio of 0.01 for Q4 2025, down 4.96% year-over-year from 0.01 in Q4 2024, and up 20.26% quarter-over-quarter from 0.01 in Q3 2025.
Powered by 
Analysis
Inhibrx Biosciences (INBX) Asset Utilization Ratio (2024 - 2026) Analysis & Trends
Inhibrx Biosciences (INBX) has reported Asset Utilization Ratio for 2 consecutive years, with 0.01 the latest figure, recorded in Q4 2025.
- In Q4 2025, Asset Utilization Ratio fell 4.96% year-over-year to 0.01; the TTM figure through Dec 2025 stood at 0.01 (down 4.96% YoY), while the FY2025 annual figure was 0.01, up 870.62% from the prior year.
- Asset Utilization Ratio advanced to 0.01 in Q4 2025 per INBX's latest filing, from 0.01 in the prior quarter.
- Across five years, Asset Utilization Ratio topped out at 0.01 in Q4 2024 and bottomed at 0.01 in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 0.47 |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 0.38 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 0.20 |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 0.69 |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 0.90 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 0.13 |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 0.54 |
| 10 | Inhibrx Biosciences | 1.91 Bn | 1.91 Bn | - | 0.01 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 0.01 |
| Dec 31, 2025 | 0.01 |
| Sep 30, 2025 | 0.01 |
| Jun 30, 2025 | 0.01 |
| Dec 31, 2024 | 0.01 |
| Sep 30, 2024 | 0.01 |